Fisetin vs Quercetin: Senolytic & Antioxidant Comparison

In the 2018 senolytic screening, fisetin showed stronger single-agent senolytic potency than quercetin. But quercetin has more human clinical data (mainly via the dasatinib+quercetin combination). Neither is proven 'better' for any health outcome in a head-to-head trial.

Both are flavonols, but fisetin (from strawberries) is studied primarily as a standalone senolytic, while quercetin (from onions/apples) is studied as a senolytic mainly in combination with dasatinib (D+Q) and has broader antioxidant/anti-inflammatory human evidence.

Combining them has not been studied. There is no evidence for additive or synergistic senolytic effects. Both have poor bioavailability and potential CYP interactions — consult a healthcare provider before combining.

Both have very poor oral bioavailability (<10%). Quercetin has more developed enhanced formulations (e.g., with piperine, phytosome) with some human PK validation; fisetin's enhanced formulations are less clinically validated.

Quercetin alone has weaker senolytic potency than fisetin in cell culture. Quercetin's senolytic clinical data comes almost entirely from the dasatinib+quercetin (D+Q) combination, not quercetin monotherapy.

Dasatinib targets senescent cell survival pathways (e.g., Src kinases, BCL-2 family) that complement quercetin's effects. The D+Q combination hits multiple anti-apoptotic networks, producing stronger senolysis than either agent alone in preclinical models.

Quercetin has substantially more published human studies (hundreds), though much of the senolytic data is from the D+Q combination. Fisetin has fewer than 15 published human trials, mostly safety/tolerability.

No. Strawberries are the primary source of fisetin (~160 μg/g). Onions are the primary source of quercetin (~300 μg/g). Apples and capers are also rich in quercetin.

Quercetin is generally less expensive and more widely available as a supplement due to its longer market history and larger supply. Fisetin supplements tend to be more expensive.

There's no clinical basis to recommend switching. Neither has proven superiority in a head-to-head trial. Discuss any changes with your healthcare provider based on your goals and medications.

Both target anti-apoptotic pathways in senescent cells, but fisetin primarily inhibits BCL-xL while the D+Q combination targets a broader set of survival networks. Whether they clear the same senescent cell subtypes in humans is unknown.

Both have antioxidant activity (Nrf2 activation, free radical scavenging). Quercetin has more published human antioxidant biomarker data; fisetin's antioxidant evidence is mostly preclinical.

No. No head-to-head clinical trial comparing fisetin and quercetin for any health outcome has been registered or published as of 2026.

Both inhibit NF-κB in cell culture, but neither has robust clinical anti-inflammatory evidence as monotherapy. Quercetin has more human biomarker data (CRP, IL-6) though results are inconsistent.

There's no evidence that fisetin can substitute for the D+Q combination, which has published human data in diabetic kidney disease and IPF. Fisetin's human evidence is primarily safety-focused. Do not replace a studied regimen with an unstudied one without medical supervision.